The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 39 results:
Author Title Type [ Year(Desc)]
Filters: Author is Akriviadis, Evangelos  [Clear All Filters]
2010
Fotiadu, A., Gagalis A., Akriviadis E., Kotoula V., Sinakos E., Karkavelas G., et al. (2010).  Clinicopathological correlations in a series of adult patients with non-alcoholic fatty liver disease.. Pathol Int. 60(2), 87-92.
Sinakos, E., Dedes I., Papalavrentios L., Drevelegas A., & Akriviadis E. (2010).  Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.. Scand J Gastroenterol. 45(4), 511-2.
2011
Imvrios, G., Vrochides D., Papanikolaou V., Fouzas I., Antoniadis N., Giakoustidis D., et al. (2011).  HCC influence on patient survival after liver transplantation for HDV cirrhosis.. Hepatogastroenterology. 58(110-111), 1654-8.
Cholongitas, E., Goulis J., Akriviadis E., & Papatheodoridis G. V. (2011).  Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review.. Liver Transpl. 17(10), 1176-90.
Lazaraki, G., Akriviadis E., Pilpilidis I., Parisi I., Tzilves D., & Tarpangos A. (2011).  Low dose of bevacizumab is safe and effective in preventing bleeding episodes in hereditary hemorrhagic telangiectasia.. Am J Gastroenterol. 106(12), 2204-6.
Sinakos, E., Selvaggi G., Papalavrentios L., Tzakis A., & Akriviadis E. (2011).  The role of sorafenib in downsizing hepatocellular carcinoma prior to liver transplantation and in treating tumor recurrence.. Ann Gastroenterol. 24(3), 228-230.
2012
Cholongitas, E., Karatapanis S., Nakouti T., Birtsou C., Skorda L., Kouvelis I., et al. (2012).  Can 24-h urine sodium excretion be replaced by spot urine sodium/potassium in patients with decompensated cirrhosis?. Liver Int. 32(1), 172-3.
2013
Papalavrentios, L., Sinakos E., Chourmouzi D., Hytiroglou P., Drevelegas K., Drevelegas A., et al. (2013).  3 Tesla diffusion-weighted MRI for assessing liver fibrosis in nonalcoholic fatty liver disease.. Hepatology. 58(1), 449-50.
Cholongitas, E., Goulis J., Arsos G., Birtsou C., Nakouti T., Papadopoulou S., et al. (2013).  Association between ratio of sodium to potassium in random urine samples and renal dysfunction and mortality in patients with decompensated cirrhosis.. Clin Gastroenterol Hepatol. 11(7), 862-7.
Pachiadakis, I., Choksi S., Ilonidis G., Akriviadis E., & Goulis I. (2013).  Letter to the editor concerning the paper: Boltjes A, Op den Brouw ML, Biesta PJ, et al. Assessment of the effect of ribavirin on myeloid and plasmacytoid dendritic cells during interferon-based therapy of chronic hepatitis B patients [Molecular Immunolog. Mol Immunol. 56(1-2), 129-30.
Kamposioras, K., Konstantara A., Kotoula V., Lakis S., Kouvatseas G., Akriviadis E., et al. (2013).  The prognostic significance of WNT pathway in surgically-treated colorectal cancer: β-catenin expression predicts for disease-free survival.. Anticancer Res. 33(10), 4573-84.
2014
Papatheodoridis, G., Goulis J., Manolakopoulos S., Margariti A., Exarchos X., Kokkonis G., et al. (2014).  Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy.. J Hepatol. 60(1), 62-8.
Cholongitas, Ε., Goulis I., Theocharidou E., Antoniadis N., Fouzas I., Giakoustidis D., et al. (2014).  Everolimus-based immunosuppression in liver transplant recipients: a single-centre experience.. Hepatol Int. 8(1), 137-45.
Cholongitas, E., Arsos G., Goulis J., Birtsou C., Haidich A-B., Nakouti T., et al. (2014).  Glomerular filtration rate is an independent factor of mortality in patients with decompensated cirrhosis.. Hepatol Res. 44(10), E145-55.
Cholongitas, E., Goulis I., Antoniadis N., Fouzas I., Imvrios G., Papanikolaou V., et al. (2014).  New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence.. Transpl Int. 27(10), 1022-8.
Karatzoglou, I., Yavropoulou M. P., Pikilidou M., Germanidis G., Akriviadis E., Papazisi A., et al. (2014).  Postprandial response of bone turnover markers in patients with Crohn's disease.. World J Gastroenterol. 20(28), 9534-40.
Cholongitas, E., Nakouti T., & Akriviadis E. (2014).  Tuberculous peritonitis after treatment for chronic hepatitis C.. Ann Gastroenterol. 27(4), 435-436.
2015
Papachrysos, N., Hytiroglou P., Papalavrentios L., Sinakos E., Kouvelis I., & Akriviadis E. (2015).  Antiviral therapy leads to histological improvement of HBeAg-negative chronic hepatitis B patients.. Ann Gastroenterol. 28(3), 374-378.
Papachrysos, N., Hytiroglou P., Papalavrentios L., Sinakos E., Kouvelis I., & Akriviadis E. (2015).  Authors' reply.. Ann Gastroenterol. 28(4), 507.
Manolakopoulos, S., Kranidioti H., Goulis J., Vlachogiannakos J., Elefsiniotis J., Kouroumalis E. A., et al. (2015).  Boceprevir for chronic HCV genotype 1 infection in treatment-experienced patients with severe fibrosis or cirrhosis: The Greek real-life experience.. Ann Gastroenterol. 28(4), 481-6.
Sinakos, E., Hytiroglou P., Chourmouzi D., & Akriviadis E. (2015).  Focal nodular hyperplasia in an individual with Abernethy malformation type 1b.. Dig Liver Dis. 47(12), 1089.
Cholongitas, E., Papatheodoridis G. V., Goulis J., Vlachogiannakos J., Karatapanis S., Ketikoglou J., et al. (2015).  The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis.. Ann Gastroenterol. 28(1), 109-117.
Dimopoulou, D., Dimitroulas T., Akriviadis E., & Garyfallos A. (2015).  Infliximab as a treatment option for patients with rheumatoid arthritis and primary biliary cirrhosis.. Rheumatol Int. 35(11), 1913-6.
Goulis, I., Karatapanis S., Akriviadis E., Deutsch M., Dalekos G. N., Raptopoulou-Gigi M., et al. (2015).  On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients.. Liver Int. 35(5), 1540-8.
Papalavrentios, L., Sinakos E., Chourmouzi D., Hytiroglou P., Drevelegas K., Constantinides M., et al. (2015).  Value of 3 Tesla diffusion-weighted magnetic resonance imaging for assessing liver fibrosis.. Ann Gastroenterol. 28(1), 118-123.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.